A Phase 2 interventional study of Thiamine and Normal saline in Hematopoietic Stem Cell Transplantation, Delirium and Thiamine Deficiency, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 2, Interventional, and Prevention
Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including health-related quality of life (HRQOL), functional status, and neuropsychiatric outcomes, in patients admitted to University of North Carolina (UNC) Hospital for allogeneic hematopoietic stem cell transplant (HSCT).
Participants: 60 adult inpatients admitted to the UNC Bone Marrow Transplant Unit for allogeneic stem cell transplant.
Procedures (methods): Participants will be admitted for allogeneic HSCT and on the day after transplant randomized to seven days of high dose IV thiamine or placebo. Thiamine levels will be measured weekly and participants will be assessed for evidence of delirium using validated measures. Validated measures will also be used to assess cognitive function, depression, post-traumatic stress symptoms, functional status, and HRQOL prior to hospitalization and at one, three, and six months after transplant.
Delirium is a common and potentially preventable neuropsychiatric complication in cancer patients receiving hematopoietic stem cell transplantation (HSCT) that has profound consequences. Among cancer patients hospitalized for HSCT, delirium occurs in approximately 40% of patients and increases the risk of mortality. Long-term, delirium in this population results in worse physical health, mental health, and quality of life. Though strategies to prevent delirium have the potential to significantly improve the lives of people living with cancer, research in this area is extremely limited. Thiamine deficiency is also ubiquitous during HSCT and a known contributor to the development of delirium in other patient populations. High dose intravenous (IV) thiamine is an evidence-based and promising treatment for delirium, but no one has studied IV thiamine as a prevention strategy.
This is a randomized double-blind controlled trial in participants undergoing allogeneic HSCT to determine if high dose IV thiamine can prevent delirium and minimize the deleterious impact of delirium on health-related quality of life (HRQOL), functional status, and other neuropsychiatric outcomes. The investigators will recruit 60 patients admitted for allogeneic HSCT at UNC, randomize them to treatment with high dose IV thiamine (n = 30) versus placebo (n = 30), and systematically evaluate all participants for delirium and related comorbidities. The investigators will use the Delirium Rating Scale (DRS) to measure the severity and duration of delirium immediately prior to transplant and after HSCT until 30 days post-transplant or discharge. If delirium is identified, the DRS will be administered daily until delirium resolves. The investigators will obtain thiamine levels and other laboratory parameters associated with delirium the day after transplant, and continue to monitor thiamine levels weekly thereafter. The investigators will also monitor HRQOL, functional status, depression, post-traumatic stress symptoms, and cognitive function prior to transplant and at one, three, and six months after transplant to elucidate the persistent impact of delirium in this population and the potential for thiamine to mitigate these negative outcomes.
Exclusion Criteria:
Thiamine 200 mg IV
Drug: Thiamine
Normal saline IV
Drug: Normal saline
200 mg IV three times daily for seven days
Also known as: Thiamine Hydrochloride Injection
Normal saline IV three times daily for seven days
Also known as: Placebo
Percentage of Participants With Delirium
Delirium incidence will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium incidence will be defined as at least one assessment with DRS \> 12.
Time frame: Assessments will occur in the week prior to transplant, then 3 times weekly post-transplant until 30 days post-transplant or discharge, whichever comes first.
Delirium Severity
Delirium severity will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The score ranges from 0 to 32 with higher scores reflecting more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. The DRS medians and ranges are reported for each group at baseline and in each week of hospitalization for thiamine and placebo groups.
Time frame: Assessments will occur in the week prior to transplant (baseline), then at least 3 times post-transplant on a weekly basis until 30 days post-transplant or discharge, whichever comes first, up to week 5
Delirium Duration
Delirium duration will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium duration will be reported as number of consecutive days during which DRS \> 12.
Time frame: Assessments will occur in the week prior to transplant, then 3 times weekly post-transplant until 30 days post-transplant or discharge, whichever comes first.
Concentration of Thiamine Status Stratified by Delirium Status
The relationship between thiamine levels at the end of the seven day administration of thiamine and the development of delirium at any point during the thirty days post-transplant or the post-transplant hospitalization, whichever comes first, will be examined. Thiamine levels (nmol/L) are presented in participants who did and did not experience delirium.
Time frame: From end of 7-day intervention period until the development of delirium at any point during the post-transplant hospitalization up to a maximum of 30 days
Change in Health-related Quality of Life Scores (Month 1)
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
Time frame: From baseline to one month post-transplant
Change in Health-related Quality of Life Scores (Month 3)
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
Time frame: Baseline to three months post-transplant
Change in Health-related Quality of Life Scores (Month 6)
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
Time frame: Baseline to six months post-transplant
Change in Depression Scores (Month 1)
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
Time frame: Baseline to one month post-transplant
Change in Depression Scores (Month 3)
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
Time frame: Baseline to three months post-transplant
Change in Depression Scores (Month 6)
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
Time frame: Baseline to six months post-transplant
Change in Post-traumatic Stress Symptom Scores (Month 1)
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
Time frame: Baseline to one month post-transplant
Change in Post-traumatic Stress Symptom Scores (Month 3)
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
Time frame: Baseline to three months post-transplant
Change in Post-traumatic Stress Symptom Scores (Month 6)
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
Time frame: Baseline to six months post-transplant
Change in Cognitive Function Scores (Month 1)
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
Time frame: From baseline to one month post-transplant
Change in Cognitive Function Scores (Month 3)
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
Time frame: Baseline to three months post-transplant
Change in Cognitive Function Scores (Month 6)
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
Time frame: From baseline to six months post-transplant
Change in Functional Status Scores (Month 1)
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
Time frame: Baseline to one month post-transplant
Change in Functional Status Scores (Month 3)
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
Time frame: From baseline to three months post-transplant
Change in Functional Status Scores (Month 6)
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
Time frame: Baseline to six months post-transplant
Participants were recruited from the UNC Bone Marrow Transplant and Cellular Therapies Unit from October 2017 through February 2020.
| Milestone | Intervention | Control |
|---|---|---|
| Started | 30 | 34 |
| Completed | 28 | 33 |
| Not completed | 2 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Inadequate drug exposure | 0 | 1 |
| Milestone | Intervention | Control |
|---|---|---|
| Started | 28 | 33 |
| Completed | 27 | 33 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Intervention | Control |
|---|---|---|
| Started | 27 | 33 |
| Completed | 26 | 30 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Milestone | Intervention | Control |
|---|---|---|
| Started | 26 | 30 |
| Completed | 24 | 28 |
| Not completed | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
Delirium incidence will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium incidence will be defined as at least one assessment with DRS \> 12.
| percentage of participants | Intervention | Control |
|---|---|---|
| Percentage of Participants With Delirium | 25 | 21 |
Delirium severity will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The score ranges from 0 to 32 with higher scores reflecting more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. The DRS medians and ranges are reported for each group at baseline and in each week of hospitalization for thiamine and placebo groups.
| score on a scale | Intervention | Control |
|---|---|---|
| Baseline | 4.0 (2.0 to 8.0) | 4.0 (2.0 to 7.0) |
| Week 1 | 4.83 (3.0 to 9.0) | 4.67 (2.67 to 15.00) |
| Week 2 | 6.50 (2.67 to 20.33) | 5.33 (2.33 to 16.00) |
| Week 3 | 6.33 (1.00 to 18.60) | 5.17 (2.00 to 17.80) |
| Week 4 | 5.50 (4.00 to 20.00) | 6.00 (5.00 to 13.50) |
| Week 5 | 20.00 (20.00 to 20.00) | 7.50 (4.00 to 8.00) |
Delirium duration will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of \> 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium duration will be reported as number of consecutive days during which DRS \> 12.
| days | Intervention | Control |
|---|---|---|
| Delirium Duration | 2.0 ± 1.2 | 4.4 ± 4.7 |
The relationship between thiamine levels at the end of the seven day administration of thiamine and the development of delirium at any point during the thirty days post-transplant or the post-transplant hospitalization, whichever comes first, will be examined. Thiamine levels (nmol/L) are presented in participants who did and did not experience delirium.
| nmol/L | Delirium | No Delirium |
|---|---|---|
| Concentration of Thiamine Status Stratified by Delirium Status | 115.6 ± 69.3 | 93.8 ± 28.5 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Health-related Quality of Life Scores (Month 1) | -7.53 ± 11.66 | -5.69 ± 11.59 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Health-related Quality of Life Scores (Month 3) | -3.96 ± 9.11 | -1.43 ± 16.79 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Health-related Quality of Life Scores (Month 6) | -4.36 ± 14.09 | 0.28 ± 12.17 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
| T-score | Intervention | Control |
|---|---|---|
| Change in Depression Scores (Month 1) | -1.34 ± 8.28 | 1.16 ± 6.12 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
| T-score | Intervention | Control |
|---|---|---|
| Change in Depression Scores (Month 3) | 0.93 ± 6.24 | 0.32 ± 9.53 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time.
| T-score | Intervention | Control |
|---|---|---|
| Change in Depression Scores (Month 6) | 0.14 ± 6.88 | -1.66 ± 7.89 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Post-traumatic Stress Symptom Scores (Month 1) | -0.52 ± 10.88 | 1.55 ± 6.92 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Post-traumatic Stress Symptom Scores (Month 3) | -1.50 ± 6.58 | 0.83 ± 5.63 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Post-traumatic Stress Symptom Scores (Month 6) | 1.79 ± 9.14 | 1.32 ± 7.00 |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Cognitive Function Scores (Month 1) | -0.70 ± 3.35 | -0.09 ± 2.76 |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Cognitive Function Scores (Month 3) | -0.12 ± 0.97 | 0.97 ± 2.82 |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Cognitive Function Scores (Month 6) | 0.71 ± 3.32 | 1.54 ± 2.87 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Functional Status Scores (Month 1) | 0.70 ± 0.67 | 0.88 ± 0.93 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Functional Status Scores (Month 3) | 0.69 ± 0.62 | 0.60 ± 0.89 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time.
| score on a scale | Intervention | Control |
|---|---|---|
| Change in Functional Status Scores (Month 6) | 0.46 ± 0.93 | 0.21 ± 0.63 |
Collected over Adverse event (AE) data were only collected from October 2017 through February 2020, during the intervention phase of the study and coinciding with participants' hospitalization for hematopoietic stem cell transplantation. This phase lasted up to 30 days for each participant. The study was completed on August 10, 2020, as secondary outcomes were collected for an additional 5 months after completion of AE data collection.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention | 1/30 (3.3%) | 0/30 (0%) | 0/30 (0%) |
| Control | 0/34 (0%) | 0/34 (0%) | 0/34 (0%) |
Only participants who met the following a priori criteria were counted: 1.) received all seven days of the treatment; 2.) received at least 17/21 (80%) scheduled study drug doses; and 3.) delirium was assessed at least weekly until the participant was found to be delirious, reached 30 days post-transplant, or was discharged.
| Age, Continuous(years) | Intervention | Control | Total |
|---|---|---|---|
| Mean | 54.9 ± 12.5 | 53.6 ± 14.7 | 54.2 ± 13.6 |
| Sex: Female, Male(Participants) | Intervention | Control | Total |
|---|---|---|---|
| Female | 11 | 13 | 24 |
| Male | 17 | 20 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Intervention | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 27 | 32 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intervention | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 9 |
| White | 25 | 27 | 52 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Intervention | Control | Total |
|---|---|---|---|
| United States | 28 | 33 | 61 |
| Education(years) | Intervention | Control | Total |
|---|---|---|---|
| Mean | 14.7 ± 2.7 | 15.3 ± 2.7 | 15.0 ± 2.7 |
| Diagnosis(Participants) | Intervention | Control | Total |
|---|---|---|---|
| Acute leukemia | 18 | 19 | 37 |
| Chronic leukemia | 2 | 5 | 7 |
| Lymphoma | 0 | 2 | 2 |
| Myelodysplastic Syndrome | 5 | 5 | 10 |
| Myeloproliferative Disorder | 2 | 1 | 3 |
| Other | 1 | 1 | 2 |
| CIBMTR Disease Risk Index(Participants) | Intervention | Control | Total |
|---|---|---|---|
| N/A | 3 | 3 | 6 |
| low | 17 | 19 | 36 |
| intermediate | 3 | 9 | 12 |
| high | 5 | 2 | 7 |
3 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UNC Lineberger Comprehensive Cancer Center